Platelet-albumin-bilirubin score and systemic immune-inflammation index for assessing the prognosis of acute ischemic stroke patients

Objectives: This study investigated the prognostic value of the systemic immune-inflammation index (SII) and platelet-albumin-bilirubin (PALBI) score in patients with acute ischemic stroke (AIS). Patients and methods: A total of 211 patients (120 males, 91 females; mean age: 70.9±13.2 years; range, 25 to 98 years) with AIS and 145 controls (72 males, 73 females; mean age: 69.4±8.4 years; range, 53 to 88 years) were included in this prospective study between March 2023 and December 2023. Demographic data and laboratory results upon admission were recorded. The SII and PALBI scores were calculated from laboratory parameters. Results: The SII was significantly higher in the stroke group compared to controls (p<0.001), while PALBI scores were similar between the groups (p=0.169). According to the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, SII was comparable across the subgroups (p=0.964), but PALBI scores were significantly higher in the cardioembolic group (p=0.002). In terms of stroke severity, SII showed no significant differences between subgroups (p=0.701); however, patients with moderate-to-severe stroke had significantly higher PALBI scores than those with minor stroke (p=0.008). Both SII (p=0.007) and PALBI scores (p=0.019) were significantly elevated in AIS patients with stroke-related complications. Conclusion: A higher PALBI score was associated with stroke severity, and both PALBI and SII values were elevated in AIS patients with complications, indicating a poor prognosis.